OBJECTIVE: The platelet receptor for von Willebrand factor, the glycoprotein Ib-IX (GPIb-IX) complex, mediates platelet adhesion at sites of vascular injury and transmits signals leading to platelet activation. von Willebrand factor/GPIb-IX interaction sequentially activates the Src family kinase Lyn (SFK), phosphoinositide 3-kinase (PI3K), and Akt, leading to activation of integrin α(IIb)β(3) and integrin-dependent stable platelet adhesion and aggregation. It remains unclear how Lyn activates the PI3K/Akt pathway after ligand binding to GPIb-IX. METHODS AND RESULTS: Using platelet-specific Rac1(-/-) mice and the Rac1 inhibitor NSC23766, we examined the role of Rac1 in GPIb-IX-dependent platelet activation. Rac1(-/-) mouse platelets and NSC23766-treated human platelets were defective in GPIb-dependent stable adhesion to von Willebrand factor under shear stress, integrin activation, thromboxane A(2) synthesis, and platelet aggregation. Interestingly, GPIb-induced activation of Rac1 and the guanine nucleotide exchange factor for Rac1, Vav, was abolished in both Lyn(-/-) and SFK inhibitor-treated platelets but was unaffected by the PI3K inhibitor LY294002, indicating that Lyn mediates activation of Vav and Rac1 independently of PI3K. Furthermore, GPIb-induced activation of Akt was abolished in Rac1-deficient platelets, suggesting that Rac1 is upstream of the PI3K/Akt pathway. CONCLUSIONS: A Lyn-Vav-Rac1-PI3K-Akt pathway mediates von Willebrand factor-induced activation of integrin α(IIb)β(3) to promote GPIb-IX-dependent platelet activation.
OBJECTIVE: The platelet receptor for von Willebrand factor, the glycoprotein Ib-IX (GPIb-IX) complex, mediates platelet adhesion at sites of vascular injury and transmits signals leading to platelet activation. von Willebrand factor/GPIb-IX interaction sequentially activates the Src family kinase Lyn (SFK), phosphoinositide 3-kinase (PI3K), and Akt, leading to activation of integrin α(IIb)β(3) and integrin-dependent stable platelet adhesion and aggregation. It remains unclear how Lyn activates the PI3K/Akt pathway after ligand binding to GPIb-IX. METHODS AND RESULTS: Using platelet-specific Rac1(-/-) mice and the Rac1 inhibitor NSC23766, we examined the role of Rac1 in GPIb-IX-dependent platelet activation. Rac1(-/-) mouse platelets and NSC23766-treated human platelets were defective in GPIb-dependent stable adhesion to von Willebrand factor under shear stress, integrin activation, thromboxane A(2) synthesis, and platelet aggregation. Interestingly, GPIb-induced activation of Rac1 and the guanine nucleotide exchange factor for Rac1, Vav, was abolished in both Lyn(-/-) and SFK inhibitor-treated platelets but was unaffected by the PI3K inhibitor LY294002, indicating that Lyn mediates activation of Vav and Rac1 independently of PI3K. Furthermore, GPIb-induced activation of Akt was abolished in Rac1-deficient platelets, suggesting that Rac1 is upstream of the PI3K/Akt pathway. CONCLUSIONS: A Lyn-Vav-Rac1-PI3K-Akt pathway mediates von Willebrand factor-induced activation of integrin α(IIb)β(3) to promote GPIb-IX-dependent platelet activation.
Authors: Hervé Falet; Karin M Hoffmeister; Ralph Neujahr; Joseph E Italiano; Thomas P Stossel; Frederick S Southwick; John H Hartwig Journal: Proc Natl Acad Sci U S A Date: 2002-12-03 Impact factor: 11.205
Authors: Ana Kasirer-Friede; Maria Rita Cozzi; Mario Mazzucato; Luigi De Marco; Zaverio M Ruggeri; Sanford J Shattil Journal: Blood Date: 2004-01-15 Impact factor: 22.113
Authors: Zhenyu Li; Xiaodong Xi; Minyi Gu; Robert Feil; Richard D Ye; Martin Eigenthaler; Franz Hofmann; Xiaoping Du Journal: Cell Date: 2003-01-10 Impact factor: 41.582
Authors: Michael Keegan Delaney; Junling Liu; Kyungho Kim; Bo Shen; Aleksandra Stojanovic-Terpo; Yi Zheng; Jaehyung Cho; Xiaoping Du Journal: Blood Date: 2014-07-25 Impact factor: 22.113
Authors: M Edward Quach; Matthew A Dragovich; Wenchun Chen; Anum K Syed; Wenpeng Cao; Xin Liang; Wei Deng; Simon F De Meyer; Guangheng Zhu; Jun Peng; Heyu Ni; Carolyn M Bennett; Ming Hou; Jerry Ware; Hans Deckmyn; X Frank Zhang; Renhao Li Journal: Blood Date: 2017-12-04 Impact factor: 22.113
Authors: Brian Estevez; Aleksandra Stojanovic-Terpo; M Keegan Delaney; Kelly A O'Brien; Michael C Berndt; Changgeng Ruan; Xiaoping Du Journal: Blood Date: 2013-04-25 Impact factor: 22.113
Authors: D Thaper; S Vahid; K M Nip; I Moskalev; X Shan; S Frees; M E Roberts; K Ketola; K W Harder; C Gregory-Evans; J L Bishop; A Zoubeidi Journal: Oncogene Date: 2017-03-13 Impact factor: 9.867
Authors: Luiza Rusu; Alexandra Andreeva; David J Visintine; Kyungho Kim; Stephen M Vogel; Aleksandra Stojanovic-Terpo; Olga Chernaya; Guoquan Liu; Farnaz R Bakhshi; Sandra L Haberichter; Hiroko Iwanari; Osamu Kusano-Arai; Nobuchika Suzuki; Takao Hamakubo; Tohru Kozasa; Jaehyung Cho; Xiaoping Du; Richard D Minshall Journal: Blood Date: 2013-09-30 Impact factor: 22.113
Authors: Brian Estevez; Kyungho Kim; M Keegan Delaney; Aleksandra Stojanovic-Terpo; Bo Shen; Changgeng Ruan; Jaehyung Cho; Zaverio M Ruggeri; Xiaoping Du Journal: Blood Date: 2015-11-19 Impact factor: 22.113